Clinical trials: Solid Tumors (Phase 1)
Selected Types of Solid Tumor
Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors
Brief Summary: The purpose of this clinical trial is to evaluate the safety, tolerability, preliminary efficacy, and immunogenicity of EVM14 administered intramuscularly (IM) alone and in combination with pembrolizumab in…
- Trial name
- NCT07095868
- Testing
- EVM14, Pembrolizumab
- Where
- 7 sites in United States, China
- Volunteers
- 94 people
- Sponsor
- Everest Medicines (Beijing) Co., Ltd.
Solid Tumor, NSCLC
A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors
This study is to evaluate the tolerability and safety of ONO-7428 in participants with unresectable advanced or recurrent solid tumors.
- Trial name
- NCT06816108
- Testing
- ONO-7428
- Where
- 15 sites in Japan
- Volunteers
- 35 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Advanced Solid Tumor
A Study of EOC237 in Patients With Advanced Solid Tumor
This research study is studying an investigational drug called EOC237 in Patients With Advanced Solid Tumor.
- Trial name
- NCT05895825
- Testing
- EOC237
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Shanghai Yiteng Jingang Bio-pharmaceutical Technology Co., Ltd
Cancer, Lymphoma
A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies
The purpose of this study is to determine a safe dose of XL844 in combination with gemcitabine, how often it should be taken, and how well people with cancer tolerate the combination of gemcitabine and XL844.
- Trial name
- NCT00475917
- Testing
- XL844, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Exelixis
Neoplasms
Initial Safety Assessment of SNS-595 for the Treatment of Solid Tumors.
The purpose of this study is to determine whether SNS-595 given intravenously once every 3 weeks is safe.
- Trial name
- NCT00091585
- Testing
- SNS-595
- Where
- 4 sites in United States
- Sponsor
- Sunesis Pharmaceuticals
Malignant Solid Tumor
A Study Using Olaparib Tablets for Subjects With Advanced Solid Tumours.
This is a phase 1 open label, 4 treatment, 4 sequence and 4 period crossover study in subjects with solid tumours no longer responding to, or eligible for standard therapies, and for whom there are no additional standard…
- Trial name
- IVIVC (NCT03553108)
- Testing
- Olaparib Treatment A, Olaparib Treatment B, Olaparib Treatment C
- Where
- 3 sites in Belgium
- Volunteers
- 18 people
- Sponsor
- AstraZeneca
Solid Tumors
Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors
Phase 1, open-labeled, dose escalation safety and tolerability study for the treatment of subjects with relapsed or refractory solid tumors.
- Trial name
- NCT00555724
- Testing
- BIIB022
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Biogen
Advanced Malignancies, Tumors
A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function
This phase I study will determine the pharmacokinetic profile of patupilone in patients with mild or moderately impaired hepatic function within 2 cycles of treatment.
- Trial name
- NCT00420524
- Testing
- Patupilone/EPO906
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Solid Tumors, Non-small Cell Lung Cancer
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
This is a first-in-human, open-label, nonrandomized, four-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX-105 and INBRX-105 in combination…
- Conditions
- Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- PDL1x41BB (NCT03809624)
- Testing
- INBRX-105 - PDL1x41BB antibody, Pembrolizumab
- Where
- 23 sites in United States
- Volunteers
- 160 people
- Sponsor
- Inhibrx Biosciences, Inc
Neoplasms Malignant
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)
This is an open-label, two-part study to evaluate the safety and tolerability of combination treatment with dalotuzumab + MK-2206, dalotuzumab + MK-0752, or dalotuzumab + ridaforolimus (MK-8669).
- Trial name
- NCT01243762
- Testing
- dalotuzumab, MK-0752, ridaforolimus
- Volunteers
- 47 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumor
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
This early phase, multicenter, open-label, single-arm study evaluated the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of atezolizumab in pediatric and young adult participants with solid…
- Trial name
- NCT02541604
- Testing
- Atezolizumab
- Where
- 30 sites in United States, Canada and 9 more
- Volunteers
- 87 people
- Sponsor
- Hoffmann-La Roche
Neoplasms
Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors
The primary objective of this trial is to determine the MTD of the combination of BIBW 2992/BIBF 1120 therapy administered concomitantly in a 28-day cycle schedule.
- Trial name
- NCT00730821
- Testing
- BIBW 2992, BIBF 1120
- Where
- 4 sites in United States
- Volunteers
- 28 people
- Sponsor
- Boehringer Ingelheim
Myeloid Malignancies, Acute Lymphocytic Leukemia
Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors
This Phase 1 study will evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD), and clinical activity of KT-253 in adult patients with relapsed or refractory (R/R) high grade myeloid malignancies, acute…
- Conditions
- Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphomas, Advanced Solid Tumors
- Trial name
- NCT05775406
- Testing
- KT-253
- Where
- 11 sites in United States
- Volunteers
- 52 people
- Sponsor
- Kymera Therapeutics, Inc.
Neoplasms
A Study of IMC-CS4 in Subjects With Advanced Solid Tumors
A dose escalation study to establish the safety profile and characterize the pharmacokinetic profile of IMC-CS4 in the treatment of subjects with advanced solid tumors refractory to standard therapy or for which no standard…
- Trial name
- NCT01346358
- Testing
- IMC-CS4
- Where
- 6 sites in United States
- Volunteers
- 52 people
- Sponsor
- Eli Lilly and Company
Solid Tumors
A Phase 1 Study of HDM2017 in Advanced Solid Tumors
This is a phase I clinical study. All subjects are patients with advanced solid tumors. The purpose of this study is to to evaluate the safety, tolerability, pharmacokinetic (PK) characteristics, and preliminary antitumor…
- Trial name
- NCT07274085
- Testing
- HDM2017
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Advanced Cancer
Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies
In this study, MGCD265, a new anticancer drug under investigation, is given daily to patients with advanced malignancies to study its safety profile.
- Trial name
- NCT00697632
- Testing
- MGCD265
- Where
- 19 sites in United States, Canada and 1 more
- Volunteers
- 180 people
- Sponsor
- Mirati Therapeutics Inc.
Advanced Solid Tumors
Study of GEC255 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation
The overall objective of this Phase 1 study is to evaluate the safety, Pharmacokinetics (PK), and anti-tumor activity of daily oral dosing with GEC255 tablets in subjects with advanced solid tumor with Kirsten Rat Sarcoma (KRAS)…
- Trial name
- NCT05768321
- Testing
- GEC255 tablets
- Where
- China
- Volunteers
- 70 people
- Sponsor
- GenEros Biopharma Hangzhou Ltd
Locally Advanced/Metastatic Solid Tumours
Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT8009
Primary objectives: To evaluate the safety and tolerability of BAT8009 in patients with advanced solid tumours. To determine the maximum tolerated dose (MTD) and recommended dose for Phase 2 (RP2D).
- Trial name
- NCT05405621
- Testing
- BAT8009 for Injection
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Bio-Thera Solutions
Solid Tumor Cancers
A First-in-human Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumour Activity of TAX2 in Patients With Relapsed/Refractory Advanced/Metastatic Solid Tumours
The purpose of this clinical trial is to investigate the treatment for adult patients suffering from advanced or metastatic solid tumours and has 2 parts to the study: the Phase 1 where ascending doses of the experimental study…
- Trial name
- APM-CT001 (NCT07688148)
- Testing
- TAX2
- Where
- 4 sites in Belgium, France
- Volunteers
- 48 people
- Sponsor
- Apmonia Therapeutics
Ewing Sarcoma, Colorectal Adenocarcinoma
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
- Trial name
- NCT03715933
- Testing
- INBRX-109, Irinotecan, Temozolomide
- Where
- 37 sites in United States, France and 4 more
- Volunteers
- 411 people
- Sponsor
- Inhibrx Biosciences, Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.